Risk of hepatotoxicity in use of febuxostat or benzbromarone: comment on the article by Sun et al

Documenti analoghi

• Febuxostat use is associated with a significantly greater risk of mild to moderate perturbation of liver function compared to benzbromarone in patients with gout: comment on the article by Sun et al
  di: Gang Wang, et al.
  Pubblicazione: (2025)
• Risk of mortality after hip fractures in rheumatoid arthritis: comment on the article by Jones et al
  di: Jui‐Man Chang, et al.
  Pubblicazione: (2025)
• Beyond the bloodstream—rethinking colchicine monitoring through a clinical lens: comment on the article by Stamp et al
  di: Yadi Li, et al.
  Pubblicazione: (2025)
• Bridging clinical relevance and equity in the cost‐effectiveness of standardized exercise therapy for osteoarthritis: comment on the article by Mazzei et al
  di: Yadi Li, et al.
  Pubblicazione: (2026)
• Withholding acetaminophen for older adults with osteoarthritis? Not so fast: comment on the article by Kaur et al
  di: Ali Ahmed, et al.
  Pubblicazione: (2025)